share_log

Cardio Diagnostics | 4: Statement of changes in beneficial ownership of securities-Director Lau Stanley K.

Cardio Diagnostics | 4: Statement of changes in beneficial ownership of securities

Cardio Diagnostics | 4：持股变动声明
美股SEC公告 ·  2024/04/09 03:23

Moomoo AI 已提取核心信息

Stanley K. Lau, associated with Cardio Diagnostics Holdings Inc. [CDIO], completed a purchase of 8,803 shares of common stock on March 31, 2024. The transaction was executed at a price of $1.42 per share, resulting in a total investment of $12,500.26. Following this transaction, Lau's direct holdings in the company amount to 100,325 shares. The acquisition was categorized as an exercise or conversion of derivative security, as per the transaction code 'M'. This financial activity reflects Lau's growing stake in the company and may be of interest to current and potential investors.
Stanley K. Lau, associated with Cardio Diagnostics Holdings Inc. [CDIO], completed a purchase of 8,803 shares of common stock on March 31, 2024. The transaction was executed at a price of $1.42 per share, resulting in a total investment of $12,500.26. Following this transaction, Lau's direct holdings in the company amount to 100,325 shares. The acquisition was categorized as an exercise or conversion of derivative security, as per the transaction code 'M'. This financial activity reflects Lau's growing stake in the company and may be of interest to current and potential investors.
与Cardio Diagnostics Holdings Holdings Inc. [CDIO] 相关的Stanley K.Lau于2024年3月31日完成了对8,803股普通股的收购。该交易以每股1.42美元的价格执行，总投资额为12,500.26美元。此次交易后，刘在公司的直接持股量为100,325股。根据交易代码 “M”，此次收购被归类为衍生证券的行使或转换。这种财务活动反映了刘在公司的股份不断增加，现有和潜在的投资者可能会对此感兴趣。
与Cardio Diagnostics Holdings Holdings Inc. [CDIO] 相关的Stanley K.Lau于2024年3月31日完成了对8,803股普通股的收购。该交易以每股1.42美元的价格执行，总投资额为12,500.26美元。此次交易后，刘在公司的直接持股量为100,325股。根据交易代码 “M”，此次收购被归类为衍生证券的行使或转换。这种财务活动反映了刘在公司的股份不断增加，现有和潜在的投资者可能会对此感兴趣。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Portage Biotech
    PRTG
    -- 9.600
    莱斯康制药
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点